Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival

2002 ◽  
Vol 17 (1) ◽  
pp. 33-41 ◽  
Author(s):  
T. Cufer ◽  
I. Vrhovec ◽  
S. Borstnar
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Locoregional Recurrence ◽  
Prognostic Significance ◽  
Plasminogen Activator Inhibitor ◽  
Recurrence Free Survival ◽  
Plasminogen Activator Inhibitor 1 ◽  
Free Survival ◽  
Activator Inhibitor

scholarly journals Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4

2009 ◽  
Vol 89 (11) ◽  
pp. 1221-1228 ◽  
Author(s):  
Chang Hyun Byon ◽  
Robert W Hardy ◽  
Changchun Ren ◽  
Selvarangan Ponnazhagan ◽  
Danny R Welch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Cell Migration ◽  
Free Fatty Acids ◽  
Plasminogen Activator ◽  
Breast Cancer Cell ◽  
Plasminogen Activator Inhibitor ◽  
Cancer Cell Migration ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

scholarly journals Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.

2000 ◽  
Vol 47 (1) ◽  
pp. 191-199 ◽  
Author(s):  
J Błasiak ◽  
B Smolarz
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Pcr Amplification ◽  
Plasminogen Activator Inhibitor ◽  
Cancer Tissue ◽  
Plasminogen Activator Inhibitor 1 ◽  
Node Negative ◽  
Node Positive ◽  
Activator Inhibitor ◽  
Pai 1

The antigen content of plasminogen activator inhibitor-1 (PAI-1) in primary breast cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumors predict poor prognosis for patients. The gene encoding PAI-1 is highly polymorphic and an insertion (5G)/deletion (4G) polymorphism in the PAI-1 gene promoter (the 4G/5G polymorphism), may have functional significance in PAI-1 expression. In the present work the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism in subjects with breast cancer were investigated. Tumor tissues were obtained from 100 postmenopausal women with node-negative and node-positive ductal breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The 4G/5G polymorphism was determined by PCR amplification using the allele specific primers. The distribution of the genotypes of the 4G/5G polymorphism in both control and patients did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distributions and allele frequencies between node-positive and node-negative patients. The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document